However, SGLT2 inhibitors did not exhibit superiority in reducing the risk of stroke (random: RR 0.97; 95% CI: 0.68–1.39; p for heterogeneity 0.07; I2 = 63%; p = 0.66) (Figure 5). Here, SLC5A2 is linked to stroke disorder.